1
|
Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F, Hayashi N, Sohn J, Teixeira de Sousa R, Brufsky AM, O'Brien CS, Schmitt F, Higgins G, Varghese D, James GD, Moh A, Livingston A, de Giorgio-Miller V. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. ESMO Open 2023; 8:101615. [PMID: 37562195 PMCID: PMC10515285 DOI: 10.1016/j.esmoop.2023.101615] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 07/05/2023] [Accepted: 07/08/2023] [Indexed: 08/12/2023] Open
Abstract
BACKGROUND Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth factor receptor 2 (HER2)-negative [immunohistochemistry (IHC) 0, 1+, or 2+/in situ hybridization (ISH) negative]; approximately 60% of BCs traditionally categorized as HER2-negative express low levels of HER2. HER2-low (IHC 1+ or IHC 2+/ISH-) status became clinically actionable with approval of trastuzumab deruxtecan to treat unresectable/metastatic HER2-low BC. Greater understanding of patients with HER2-low disease is urgently needed. PATIENTS AND METHODS This global, multicenter, retrospective study (NCT04807595) included tissue samples from patients with confirmed HER2-negative unresectable/metastatic BC [any hormone receptor (HR) status] diagnosed from 2014 to 2017. Pathologists rescored HER2 IHC-stained slides as HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2 IHC 0 after training on low-end expression scoring using Ventana 4B5 and other assays at local laboratories (13 sites; 10 countries) blinded to historical scores. HER2-low prevalence and concordance between historical scores and rescores were assessed. Demographics, clinicopathological characteristics, treatments, and outcomes were examined. RESULTS In rescored samples from 789 patients with HER2-negative unresectable/metastatic BC, the overall HER2-low prevalence was 67.2% (HR positive, 71.1%; HR negative, 52.8%). Concordance was moderate between historical and rescored HER2 statuses (81.3%; κ = 0.583); positive agreement was numerically higher for HER2-low (87.5%) than HER2 IHC 0 (69.9%). More than 30% of historical IHC 0 cases were rescored as HER2-low overall (all assays) and using Ventana 4B5. There were no notable differences between HER2-low and HER2 IHC 0 in patient characteristics, treatments received, or clinical outcomes. CONCLUSIONS Approximately two-thirds of patients with historically HER2-negative unresectable/metastatic BC may benefit from HER2-low-directed treatments. Our data suggest that HER2 reassessment in patients with historical IHC 0 scores may be considered to help optimize selection of patients for treatment. Further, accurate identification of patients with HER2-low BC may be achieved with standardized pathologist training.
Collapse
Affiliation(s)
- G Viale
- Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.
| | - M Basik
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada
| | - N Niikura
- Tokai University School of Medicine, Isehara, Kanagawa Prefecture, Japan
| | - E Tokunaga
- National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka Prefecture, Japan
| | - S Brucker
- Research Institute for Women's Health, University of Tübingen, Tübingen, Germany
| | - F Penault-Llorca
- Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, France
| | - N Hayashi
- St Luke's International Hospital, Tokyo, Tokyo Prefecture, Japan
| | - J Sohn
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
| | | | - A M Brufsky
- University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh, USA
| | - C S O'Brien
- The Christie NHS Foundation Trust, Manchester, UK
| | - F Schmitt
- Medical Faculty of the University of Porto, CINTESIS@RISE (Health Research Network), Molecular Pathology Unit, Ipatimup, Porto, Portugal
| | - G Higgins
- Victorian Cancer Biobank, Melbourne, Australia
| | - D Varghese
- Epidemiology, Global Real World Evidence Generation, OBU Medical, AstraZeneca, Gaithersburg, USA
| | - G D James
- Medical Statistics Consultancy Ltd, London, UK
| | - A Moh
- Daiichi Sankyo, Inc., Basking Ridge, USA
| | - A Livingston
- Global Medical Affairs, Medical Breast, OBU Medical, AstraZeneca, City House, Cambridge, UK
| | - V de Giorgio-Miller
- Global Medical Affairs, Medical Breast, OBU Medical, AstraZeneca, City House, Cambridge, UK
| |
Collapse
|
2
|
Illert AL, Stenzinger A, Bitzer M, Horak P, Gaidzik VI, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf CP, Hallek M, Brümmendorf TH, Albers P, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts CH, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann MW, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, Budczies J, Werner M, Nikolaou K, Beer AJ, Tabatabai G, Weichert W, Keilholz U, Boerries M, Kohlbacher O, Duyster J, Thimme R, Seufferlein T, Schirmacher P, Malek NP. The German Network for Personalized Medicine to enhance patient care and translational research. Nat Med 2023:10.1038/s41591-023-02354-z. [PMID: 37280276 DOI: 10.1038/s41591-023-02354-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Affiliation(s)
- A L Illert
- Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Department of Medicine III, Faculty of Medicine, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany
- Center for Personalized Medicine (ZPM), Freiburg, Germany
- Center for Personalized Medicine (ZPM), Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
- Bavarian Cancer Research Center (BZKF), Partner Site TU Munich, Munich, Germany
| | - A Stenzinger
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
- Center for Personalized Medicine (ZPM), Heidelberg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Germany
| | - M Bitzer
- Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
- Center for Personalized Medicine (ZPM), Tübingen, Germany
| | - P Horak
- Center for Personalized Medicine (ZPM), Heidelberg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Germany
- Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
| | - V I Gaidzik
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
- Center for Personalized Medicine (ZPM), Ulm, Germany
| | - Y Möller
- Center for Personalized Medicine (ZPM), Tübingen, Germany
- M3 Research Institute University Hospital Tübingen, Tübingen, Germany
| | - J Beha
- Center for Personalized Medicine (ZPM), Tübingen, Germany
| | - Ö Öner
- Center for Personalized Medicine (ZPM), Tübingen, Germany
| | - F Schmitt
- Center for Personalized Medicine (ZPM), Tübingen, Germany
| | - S Laßmann
- Center for Personalized Medicine (ZPM), Freiburg, Germany
- Institute for Surgical Pathology, Medical Center, University of Freiburg, Freiburg, Germany
| | - S Ossowski
- Center for Personalized Medicine (ZPM), Tübingen, Germany
- Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
- Institute for Bioinformatics and Medical Informatics (IBMI), University of Tübingen, Tübingen, Germany
| | - C P Schaaf
- Center for Personalized Medicine (ZPM), Heidelberg, Germany
- Institute of Human Genetics, Heidelberg University, Heidelberg, Germany
| | - M Hallek
- Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany
- Center for integrated Oncology (CIO-ABCD), Aachen-Bonn-Cologne-Düsseldorf, Germany
| | - T H Brümmendorf
- Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
- Center for integrated Oncology (CIO-ABCD), Aachen-Bonn-Cologne-Düsseldorf, Germany
| | - P Albers
- Department of Urology, Heinrich-Heine University, Medical Faculty, Düsseldorf, Germany
- Center for integrated Oncology (CIO-ABCD), Aachen-Bonn-Cologne-Düsseldorf, Germany
| | - T Fehm
- Department of Gynecology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
- Center for integrated Oncology (CIO-ABCD), Aachen-Bonn-Cologne-Düsseldorf, Germany
| | - P Brossart
- Department of Oncology, Hematology, Stem Cell Transplantation, Cell- and Immunotherapies, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany
- Center for integrated Oncology (CIO-ABCD), Aachen-Bonn-Cologne-Düsseldorf, Germany
| | - H Glimm
- Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT), Dresden, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany
- German Cancer Consortium (DKTK), Dresden, Germany
| | - D Schadendorf
- Department of Dermatology, University Duisburg-Essen, University Hospital Essen, Essen, Germany
- German Cancer Consortium (DKTK) Partner Site, Essen, Germany
- National Center for Tumor Diseases (NCT), NCT-West, Campus Essen, Essen, Germany
- Westdeutsches Tumorzentrum (WTZ), Essen, Germany
- Research Alliance Ruhr - Research Center One Health, University Duisburg-Essen, Essen, Germany
| | - A Bleckmann
- Department of Medicine A: Hematology, Oncology, and Pneumology, University Hospital Münster (UKM), Münster, Germany
- West German Cancer Center, University Hospital Münster, Münster, Germany
| | - C H Brandts
- University Cancer Center (UCT) Frankfurt-Marburg, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
- German Cancer Consortium (DKTK) Partner Site, Frankfurt, Germany
| | - I Esposito
- Institute of Pathology, Heinrich-Heine University and University Hospital, Düsseldorf, Germany
- Center for Personalized Medicine (ZPM), Düsseldorf, Germany
| | - E Mack
- Department of Hematology, Oncology and Immunology, University Hospital Marburg and Philipps-University, Marburg, Germany
| | - C Peters
- Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany
- German Cancer Consortium (DKTK) Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Freiburg, Germany
- Comprehensive Cancer Center Freiburg (CCCF), Freiburg, Germany
| | - C Bokemeyer
- Department of Oncology, Hematology and BMT with section of Pneumology, University of Hamburg, Hamburg, Germany
| | - S Fröhling
- Center for Personalized Medicine (ZPM), Heidelberg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Germany
- Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
| | - T Kindler
- University Cancer Center, University Medical Center Mainz, Johannes Gutenberg-University, Mainz, Germany
- German Cancer Consortium (DKTK) Partner Site Mainz, Mainz, Germany
| | - H Algül
- Institute for Tumor Metabolism, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
- Comprehensive Cancer Center Munich TUM, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
| | - V Heinemann
- Comprehensive Cancer Center Munich, Klinikum Großhadern, Ludwig Maximilian University of Munich, Munich, Germany
- Department of Medicine III, Klinikum Großhadern, Ludwig Maximilian University of Munich, Munich, Germany
| | - H Döhner
- Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany
| | - R Bargou
- Comprehensive Cancer Center Mainfranken, Uniklinikum Würzburg, Würzburg, Germany
- Bavarian Cancer Research Center (BZKF), Partner Site Würzburg, Würzburg, Germany
| | - V Ellenrieder
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Germany
| | - P Hillemanns
- Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany
| | - F Lordick
- Comprehensive Cancer Center Central Germany and University Cancer Center Leipzig,, University Medicine Leipzig, Leipzig, Germany
| | - A Hochhaus
- Comprehensive Cancer Center Central Germany and Department of Hematology and Internal Oncology, Universitätsklinikum Jena, Jena, Germany
| | - M W Beckmann
- University Hospital Erlangen, Department of Obstetrics and Gynecology, Friedrich-Alexander-Universität Erlangen, Erlangen, Germany
- Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nuremberg, Erlangen, Germany
- Bavarian Cancer Research Center (BZKF), Partner Site Erlangen, Erlangen, Germany
| | - T Pukrop
- Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany
- Comprehensive Cancer Center Ostbayern, Regensburg, Germany
- Bavarian Cancer Research Center (BZKF), Partner Site Regensburg, Regensburg, Germany
| | - M Trepel
- Department of Hematology and Medical Oncology, Augsburg University Hospital, Augsburg, Germany
- Comprehensive Cancer Center Augsburg, CCC Alliance WERA, Augsburg, Germany
- Bavarian Cancer Research Center (BZKF), Partner Site Augsburg, Augsburg, Germany
| | - L Sundmacher
- Department of Health Services Management, Ludwig-Maximilians-Universität, Munich, Germany
| | - S Wesselmann
- Deutsche Krebsgesellschaft (DKG), Berlin, Germany
| | | | | | - O Heinze
- Department Medical Information Systems, University Hospital Heidelberg, Heidelberg, Germany
| | - J Budczies
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
- Center for Personalized Medicine (ZPM), Heidelberg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Germany
| | - M Werner
- Center for Personalized Medicine (ZPM), Freiburg, Germany
- Institute for Surgical Pathology, Medical Center, University of Freiburg, Freiburg, Germany
- German Cancer Consortium (DKTK) Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Freiburg, Germany
- Comprehensive Cancer Center Freiburg (CCCF), Freiburg, Germany
| | - K Nikolaou
- Department of Diagnostic and Interventional Radiology, Eberhard Karls University Tübingen, Tübingen, Germany
| | - A J Beer
- Department of Nuclear Medicine, Ulm University Hospital, Ulm, Germany
| | - G Tabatabai
- Department of Neurology and Interdisciplinary Neuro-Oncology, Center for Neuro-Oncology, University Hospital Tübingen, Tübingen, Germany
- Comprehensive Cancer Center Tübingen-Stuttgart, Stuttgart, Germany
| | - W Weichert
- Center for Personalized Medicine (ZPM), Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
- Institute of Pathology, Technische Universität München, Munich, Germany
- German Cancer Consortium (DKTK) Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Munich, Germany
- Bavarian Cancer Research Center (BZKF), Partner Site TU Munich, Munich, Germany
| | - U Keilholz
- Charité Comprehensive Cancer Center, Charité, Berlin, Germany
| | - M Boerries
- Center for Personalized Medicine (ZPM), Freiburg, Germany
- German Cancer Consortium (DKTK) Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Freiburg, Germany
- Institute of Medical Bioinformatics and Systems Medicine (IBSM), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Comprehensive Cancer Center Freiburg (CCCF), Freiburg, Germany
| | - O Kohlbacher
- Center for Personalized Medicine (ZPM), Tübingen, Germany
- Institute for Bioinformatics and Medical Informatics (IBMI), University of Tübingen, Tübingen, Germany
- Institute for Translational Bioinformatics, University Medical Center, Tübingen, Germany
- Department of Computer Science, Applied Bioinformatics, University of Tübingen, Tübingen, Germany
| | - J Duyster
- Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- Center for Personalized Medicine (ZPM), Freiburg, Germany
- German Cancer Consortium (DKTK) Partner Site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Freiburg, Germany
- Comprehensive Cancer Center Freiburg (CCCF), Freiburg, Germany
| | - R Thimme
- Center for Personalized Medicine (ZPM), Freiburg, Germany
- Comprehensive Cancer Center Freiburg (CCCF), Freiburg, Germany
- Department of Medicine II, Freiburg, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - T Seufferlein
- Center for Personalized Medicine (ZPM), Ulm, Germany
- Department of Internal Medicine I, University Hospital, University of Ulm, Ulm, Germany
| | - P Schirmacher
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
- Center for Personalized Medicine (ZPM), Heidelberg, Germany
- German Cancer Consortium (DKTK), Heidelberg, Germany
| | - N P Malek
- Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany.
- Center for Personalized Medicine (ZPM), Tübingen, Germany.
- M3 Research Institute University Hospital Tübingen, Tübingen, Germany.
| |
Collapse
|
3
|
Valente A, Costa M, Pinto R, Cirnes L, Augusto I, Schmitt F. PAM50 genomic test in the management of early breast cancer – the importance of clinical-pathological data. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01559-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Vaubourdolle M, Cortey A, Delatour V, Poupon C, Rota M, Schmitt F, Mailloux A. M270 Harmonization of total bilirubin measurement for improved diagnosis and management of neonatal jaundice. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
5
|
Cesbron M, Durand JB, Ladureau-Fritsch L, Greze C, Schmitt F, Pirrello O, Bettahar K, Ohl J, Rongieres C, Lichtblau I, Saussine C, Mark M, Teletin M. P–116 A 9-year monocentric retrospective analysis of glutaraldehyde-fixed and semithin section of testicular biopsies and TESE in azoospermic patients. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
What is the outcome of testicular sperm extraction (TESE) after microinjection of frozen–thawed sperm and the correlation with histological analysis in azoospermic patients?
Summary answer
In our cohort of 240 azoospermic patients, sperm could be retrieved in 167 patients (69.6%).
What is known already
Testicular biopsy is a crucial assessment in reproductive practice with diagnostic and prognostic importance for ICSI. Divers histological procedures are used throughout the centres. There is increasing need to accurately analyse histological biopsies in order to characterise different type of spermatogenic failure and allows data storage of value in clinical practice and research. Compared with Bouin’s and formalin, glutaraldehyde fixed and semithin section of testicular biopsies have the advantage of yielding not only good cellular morphology but also it allows the possibility of performing electron microscopy.
Study design, size, duration
This is a monocentric retrospective study of TESE practice in azoospermic patients in Strasbourg University Hospital from February 2011 to December 2019.
Participants/materials, setting, methods
A total of 240 azoospermic patients underwent TESE followed by sperm cryopreservation when sperm were present and data of histological analysis and clinical outcome of ICSI were analysed. The analysis include initial hormonal status, type of azoospermia, body max index, classification of histological findings, freezing rate and outcome of ICSI-IVF procedure.
Main results and the role of chance
The mean age of 240 patients was 34.5 years. Out of all patients, 42% were diagnosed with obstructive azoospermia (OA) and 58% patients with non-obstructive azoospermia (NOA). There was no correlation of sperm retrieval with the body mass index. Overall, sperm could be retrieved in 69.6% patients. Spermatozoa were always successfully recovered in patients with normal testicular histological findings, 41.7% patients (n 100). Histological analysis revealed a Sertoli cell-only (SCO) syndrome in 27.5% cases (n 66), hypospermatogenesis in 14.2% (n 34), germ cell arrest in 7.9 (n 19) and mixed pattern in 8.3% (n 20).
In patients with serum FSH concentrations >12 IU/l, 46% of patients (n 42) sperm were present at TESE. In patients with no sperm retrieval, 31.5% had normal FSH levels. Out of all men with elevated FSH, 63% had SCO pattern, 4% germ cell arrest, 21% hypospermatogenesis and 12% mixt patterns. In the group of patients with no sperm retrieved at TESE, histological analysis showed SCO in 69.9% cases, germ cell arrest in 15% and hypospermatogenesis in 9.6% of cases. Out of 167 patients with TESE and sperm cryopreservation, 126 patients undergone ICSI-IVF procedure and 80 babies were born.
Limitations, reasons for caution
This study is a retrospective analysis in a single centre. The cohort was not compared with groups of patients with different histological and fixation techniques.
Wider implications of the findings: Accurate histological diagnosis is a prerequisite for research and clinical data collection and open the possibilities to include patients with NOA in subsequent detailed genetic screen.
Trial registration number
NA
Collapse
Affiliation(s)
- M Cesbron
- BIO67, Laboratoire d’analyse de biologie médicale, Strasbourg, France
| | - J B Durand
- Hôpitaux Universitaires de Strasbourg, Laboratoire de biologie de la reproduction - CECOS, Strasbourg, France
| | - L Ladureau-Fritsch
- Hôpitaux Universitaires de Strasbourg, Laboratoire de biologie de la reproduction – CECOS, Strasbourg, France
| | - C Greze
- Hôpitaux Universitaires de Strasbourg, Laboratoire de biologie de la reproduction – CECOS, Strasbourg, France
| | - F Schmitt
- Hôpitaux Universitaires de Strasbourg, Laboratoire de biologie de la reproduction – CECOS, Strasbourg, France
| | - O Pirrello
- Hôpitaux Universitaires de Strasbourg, Centre d’aide médicale à la procréation, Strasbourg, France
| | - K Bettahar
- Hôpitaux Universitaires de Strasbourg, Centre d’aide médicale à la procréation, Strasbourg, France
| | - J Ohl
- Hôpitaux Universitaires de Strasbourg, Centre d’aide médicale à la procréation, Strasbourg, France
| | - C Rongieres
- Hôpitaux Universitaires de Strasbourg, Centre d’aide médicale à la procréation, Strasbourg, France
| | - I Lichtblau
- Hôpitaux Universitaires de Strasbourg, Laboratoire de biologie de la reproduction – CECOS, Strasbourg, France
| | - C Saussine
- Hôpitaux Universitaires de Strasbourg- Unistra, Service d’urologie, Strasbourg, France
| | - M Mark
- IGBMC- Hôpitaux Universitaires de Strasbourg- Unistra, Functional genomics and cancer, Strasbourg, France
| | - M Teletin
- IGBMC- CECOS- Hôpitaux Universitaires de Strasbourg- Unistra, Functional genomics and cancer, Strasbourg, France
| |
Collapse
|
6
|
Kukhlenko R, Frantsev R, Buentjen L, Voges J, Kukhlenko O, Haghikia A, Frodl T, Schmitt F. P 20. Stimulus-dependent behavioural disorder in patients with ANT-DBS for Epilepsy. Clin Neurophysiol 2021. [DOI: 10.1016/j.clinph.2021.02.342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Quintero J, Slevin J, Koehl L, Guduru Z, Yamasaki T, Gurwell J, Hines T, Welleford A, Granholm-Bentley A, Schmitt F, Gerhardt G, van Horne C. DBS Plus: a clinical trial platform for combining delivery of investigational therapeutics with deep brain stimulation surgery in patients with parkinson’s disease. Cytotherapy 2021. [DOI: 10.1016/s1465324921004801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Thalman S, Van Pelt KL, Lin AL, Johnson NF, Jicha G, Caban-Holt A, Robertson W, Lightner D, Powell D, Head E, Schmitt F. A preliminary study of cerebral blood flow, aging and dementia in people with Down syndrome. J Intellect Disabil Res 2020; 64:934-945. [PMID: 32996650 PMCID: PMC8244721 DOI: 10.1111/jir.12784] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 07/28/2020] [Accepted: 09/06/2020] [Indexed: 05/02/2023]
Abstract
BACKGROUND People with Down syndrome (DS) develop Alzheimer's disease (AD) at an earlier age of onset than those with sporadic AD. AD neuropathology is typically present in DS by 40 years of age with an onset of dementia approximately 10 years later. This early onset is due to the overexpression of amyloid precursor protein from the third copy of chromosome 21. Cerebrovascular neuropathology is thought to contribute in 40-60% of cases sporadic AD. However, the vascular contribution to dementia in people with DS has been relatively unexplored. We hypothesised that vascular perfusion is compromised in older adults with DS relative to younger individuals and is further exacerbated in those with dementia. METHOD Cerebral blood flow (CBF) was measured using pulsed arterial spin labelling in 35 cognitively characterised adults with DS (26-65 years). DS participants were also compared with 15 control subjects without DS or dementia (26-65 years). Linear regression evaluated the difference in CBF across groups and diagnosis along with assessing the association between CBF and cognitive measures within the DS cohort. RESULTS Cerebral blood flow was significantly lower among DS participants with probable AD compared with controls (P = 0.02) and DS participants with no dementia (P = 0.01). Within the DS cohort, CBF was significantly associated with the Severe Impairment Battery (SIB) measure and the Dementia Questionnaire for People with Learning Disabilities (DLD) rating (F3,25 = 5.13; P = 0.007). Both the SIB (β = 0.74; t = 2.71; P = 0.01) and DLD (β = -0.96; t = -3.87; P < 0.001) indicated greater impairment as global CBF decreased. Age was significantly associated with CBF among participants with DS. There was a non-linear effect of age, whereby CBF declined more rapidly after 45 years of age. CONCLUSIONS This preliminary study of CBF in DS indicates that cerebrovascular pathology may be a significant contributor to dementia in DS. CBF was associated with diagnosis, cognition and age. Notably, CBF decreases at a greater rate after age 45 and may represent a significant prodromal event in AD progression.
Collapse
Affiliation(s)
- S Thalman
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
| | - K L Van Pelt
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
| | - A-L Lin
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
- Department of Pharmacology & Nutritional Sciences, University of Kentucky, Lexington, KY, USA
| | - N F Johnson
- College of Health Sciences, Department of Physical Therapy, University of Kentucky, Lexington, KY, USA
| | - G Jicha
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
- Department of Neurology, University of Kentucky, Lexington, KY, USA
| | - A Caban-Holt
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
| | - W Robertson
- Department of Neurology, University of Kentucky, Lexington, KY, USA
| | - D Lightner
- Department of Neurology, University of Kentucky, Lexington, KY, USA
| | - D Powell
- Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky, Lexington, KY, USA
| | - E Head
- Department of Pathology & Laboratory Medicine, Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, CA, USA
| | - F Schmitt
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
- Department of Neurology, University of Kentucky, Lexington, KY, USA
| |
Collapse
|
9
|
Schmitt F, Brinke-Seiferth S, Fiedler J. Digitale Membranchromatographie als neuartige Trenntechnik zur Optimierung von biotechnologischen Downstream‐Prozessen. CHEM-ING-TECH 2020. [DOI: 10.1002/cite.202055248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- F. Schmitt
- i3 Membrane GmbH Theodorstr. 41P 22761 Hamburg Deutschland
| | | | - J. Fiedler
- i3 Membrane GmbH Bautzner Landstr. 45 01454 Radeberg Deutschland
| |
Collapse
|
10
|
Horta R, Schmitt F, Pereira N, Gervásio H. ACCIDENTAL FINDING OF SYNCHRONOUS BILATERAL DUCTAL CARCINOMA IN SITU IN A YOUNG MAN REFERRED TO MASTECTOMY DUE TO GYNECOMASTIA - AND WHAT IF LIPOSUCTION HAVE BEEN USED? CASE REPORT. Acta Chir Plast 2020; 62:46-49. [PMID: 32911942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Breast male cancer is a rare condition. We report a case of a synchronous bilateral ductal carcinoma in situ (DCIS) which developed in a 26-year-old man with long-standing gynecomastia. He underwent bilateral subcutaneous mastectomy. Histology revealed bilateral pure DCIS. There was no identifiable causative factor for the development of bilateral DCIS, and there was no family history of the disease. No other treatment was required, and after 18 months there were no signs of local recurrence. This case highlights the importance of staying vigilant regarding the presence of malignancy in normally benign conditions. Liposuction has become a very useful technique for gynecomastia correction, however, there is a risk of dissemination of an unknown malignant tumor. In atypical cases, en bloc surgical excision should be performed.
Collapse
|
11
|
Brandão M, Guisseve A, Bata G, de Morais G, Alberto M, Schmitt F, Lorenzoni C, Tulsidás S, Lunet N, Carrilho C. HIV infection in breast cancer patients from Mozambique: A prospective cohort study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz101.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Gonçalves A, Martins M, Pires M, Alves A, Schmitt F, Bastos E, Gama A. Epidermal growth factor receptor expression in primary and metastatic canine mammary carcinomas. J Comp Pathol 2019. [DOI: 10.1016/j.jcpa.2018.10.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Abstract
In this paper, we aim to focus on false positive results in the evaluation of thyroid aspirations, covering cystic, inflammatory, follicular and oncocytic lesions, papillary carcinoma, and medullary carcinoma of thyroid. The recently described entity noninvasive follicular thyroid neoplasm with papillary-like nuclear features is also discussed detailing the impact of its introduction on the sensitivity and specificity of thyroid FNA, as well as the use of molecular tests for diagnostics. Medicolegal issues in relation to current practice in English law are also described.
Collapse
Affiliation(s)
- D C Malheiros
- Faculdade de Ciências, Médicas da Santa Casa de São Paulo, São Paulo, Brasil.,IPATIMUP, Institute of Molecular Pathology and Immunology of University of Porto, Porto, Portugal
| | - S Canberk
- IPATIMUP, Institute of Molecular Pathology and Immunology of University of Porto, Porto, Portugal.,I3S, Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal.,Department of Pathology subdivision of Cytopathology, Acibadem University, Atasehir-Istanbul, Turkey
| | - D N Poller
- Department of Pathology, Queen Alexandra Hospital, Portsmouth, UK
| | - F Schmitt
- IPATIMUP, Institute of Molecular Pathology and Immunology of University of Porto, Porto, Portugal.,I3S, Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal.,Medical Faculty of Porto University, Porto, Portugal
| |
Collapse
|
14
|
Schmitt F, Aurlien H, Brøgger J, Hirsch L, Schomer D, Trinka E, Pressler R, Wennberg R, Visser G, Eisermann M, Diehl B, Lesser R, Kaplan P, The Tich S, Lee J, Martins-da-Silva A, Stefan H, Neufeld M, Rubboli G, Fabricius M, Gardella E, Terney D, Meritam P, Eichele T, Asano E, Cox F, van Emde Boas W, Mameniskiene R, Marusic P, Zárubová J, Rosén I, Fuglsang-Frederiksen A, Ikeda A, MacDonald D, Terada K, Ugawa Y, Zhou D, Herman S, Beniczky S. Standardisierter Computer-basiert-organisierter Report des EEG (SCORE) – Eine strukturierende Form der EEG-Befundung. KLIN NEUROPHYSIOL 2018. [DOI: 10.1055/s-0043-125304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
ZusammenfassungEine 2013 von der „International Federation of Clinical Neurophysiology“ gegründete Taskforce hat eine international konsensfähige EEG-Terminologie entwickelt. Im Folgenden soll das Resultat – die 2. Version des Standardized Computer-based Organized Reporting of EEG (SCORE) - vorgestellt werden. Die Terminologie wurde im Rahmen eines Softwarepaketes (SCORE-EEG) in der klinischen Praxis an über 12.000 EEGs getestet. Die Auswahl der Begriffe ist kontextabhängig: die initiale Auswahl bestimmt, welche weiteren Auswahlmöglichkeiten zur Verfügung stehen. Im Verlauf wird automatisch ein Befund erstellt und dessen Einzelmerkmale in eine Datenbank eingespeist. SCORE verfügt über Module spezifisch für die Befundung epileptischer Anfälle, sowie charakteristischer neonataler und intensivmedizinische EEG-Merkmale. SCORE ist nicht nur ein nützliches Werkzeug im ambulanten, klinischen und wissenschaftlichen Setting, es erleichtert auch Qualitätssicherung, Datenaustausch und die EEG-Aus und Weiterbildung.
Collapse
Affiliation(s)
- F Schmitt
- Universitätsklinik für Neurologie, Otto-von-Guericke Universität, Magdeburg, Deutschland
| | - H Aurlien
- Department of Neurology, Haukeland University Hospital and Department of Clinical Medicine, University of Bergen, Bergen, Norwegen
| | - J Brøgger
- Department of Neurology, Haukeland University Hospital and Department of Clinical Medicine, University of Bergen, Bergen, Norwegen
| | - L Hirsch
- Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, CT, USA
| | - D Schomer
- Department of Neurology, Laboratory of Clinical Neurophysiology, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA
| | - E Trinka
- Universitätskliniklinik für Neurologie, Christian Doppler Klinik, Paracelsus Medizinische Universität und Zentrum für Kognitive Neurowissenschaften Salzburg, Österreich und Institut für Public Health, Versorgungsforschung & HTA, UMIT, Hall in Tirol, Österreich
| | - R Pressler
- Department of Clinical Neurophysiology, Great Ormond Street Hospital und Clinical Neuroscience, UCL Great Ormond Street Institute of Child Health, London, Großbritannien
| | - R Wennberg
- Krembil Neuroscience Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Kanada
| | - G Visser
- Department of Clinical Neurophysiology, Stichting Epilepsie Instellingen Nederland (SEIN), Niederlande
| | - M Eisermann
- Department of Clinical Neurophysiology, Necker Enfants Malades Hospital, Paris, Frankreich und INSERM U1129, Paris, France, Paris Descartes University, CEA, Gif sur Yvette, Paris, Frankreich
| | - B Diehl
- University College London, Department of Clinical and Experimental Epilepsy, Queen Square, London, Großbritannien
| | - R Lesser
- Johns Hopkins Medical Institutions, Baltimore, MD, USA
| | - P Kaplan
- Johns Hopkins University School of Medicine, Baltimore, Maryland, MD, USA
| | - S The Tich
- Department of Pediatric Neurology, University Hospital of Lille, Lille, Frankreich
| | - J Lee
- Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA
| | - A Martins-da-Silva
- Department of Neurophysiology, Hospital Santo António and UMIB/ICBAS – University of Porto, Porto, Portugal
| | - H Stefan
- Abteilung für Neurologie und Biomagnetismus, Universitätsklinikum Erlangen, Deutschland
| | - M Neufeld
- Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - G Rubboli
- Department of Neurology, Danish Epilepsy Center, Dianalund and University of Copenhagen, Kopenhagen, Dänemark
| | - M Fabricius
- Department of Clinical Neurophysiology, Rigshospitalet, Kopenhagen, Dänemark
| | - E Gardella
- University of Southern Denmark, Odense, Dänemark
- Department of Clinical Neurophysiology, Danish Epilepsy Centre, Dianalund, Dänemark
| | - D Terney
- Department of Clinical Neurophysiology, Danish Epilepsy Centre, Dianalund, Dänemark
| | - P Meritam
- Department of Clinical Neurophysiology, Danish Epilepsy Centre, Dianalund, Dänemark
| | - T Eichele
- Department of Neurology, Haukeland University Hospital and Department of Biological and Medical Psychology, University of Bergen, Norwegen
| | - E Asano
- Departments of Pediatrics and Neurology, Children’s Hospital of Michigan, Wayne State University, Detroit, Michigan, US
| | - F Cox
- Department of Clinical Neurophysiology, Stichting Epilepsie Instellingen Nederland (SEIN), Niederlande
| | - W van Emde Boas
- Department of Clinical Neurophysiology, Stichting Epilepsie Instellingen Nederland (SEIN), Niederlande
| | - R Mameniskiene
- Department of Neurology and Neurosurgery, Center for Neurology, Vilnius University, Vilnius, Litauen
| | - P Marusic
- Department of Neurology, Charles University, 2nd Faculty of Medicine, Motol University Hospital, Tschechische Republik
| | - J Zárubová
- Department of Neurology, Charles University, 2nd Faculty of Medicine, Motol University Hospital, Tschechische Republik
| | - I Rosén
- Department of Clinical Sciences, University of Lund, Lund, Schweden
| | | | - A Ikeda
- Department of Epilepsy, Movement Disorders and Physiology Kyoto University Graduate School of Medicine Shogoin, Sakyo-ku Kyoto, Japan
| | - D MacDonald
- Department of Neurosciences, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabien
| | - K Terada
- Department of Neurology, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan
| | - Y Ugawa
- Department of Neurology, School of Medicine, Fukushima Medical University, Fukushima, Japan
| | - D Zhou
- Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - S Herman
- Department of Neurology, Laboratory of Clinical Neurophysiology, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA
| | - S Beniczky
- Department of Clinical Neurophysiology, Danish Epilepsy Centre, Dianalund, Dänemark
- Department of Clinical Neurophysiology, Aarhus University, Aarhus, Dänemark
| |
Collapse
|
15
|
Riquin E, Schmitt F, Bouhours-Nouet N, Beaumesnil M, Dinomais M, Malka J, Robin M, Coutant R, Duverger P. Laparoscopic adjustable gastric banding in adolescents with severe obesity: Psychological aspects, decision makers of surgery, and 2-year outcomes. A case series. Arch Pediatr 2018; 25:269-273. [PMID: 29656036 DOI: 10.1016/j.arcped.2018.02.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 01/31/2018] [Accepted: 02/18/2018] [Indexed: 11/18/2022]
Abstract
BACKGROUND The results of medical treatment of severe obesity in the adolescent population (balanced diet and physical activity) are often unsatisfactory, and bariatric surgery is questioned. The psychological determinants for requesting bariatric surgery in these adolescents are unclear. The objective of this study was to report the psychiatric and psychological aspects as well as the determinants of the medical decision for surgery in a cohort of obese adolescents requesting bariatric surgery by laparoscopic adjustable gastric banding. METHODS Thirty-five adolescents (12.3-17.7 years of age), were recruited from January 2007 to December 2012. Semistructured interviews were conducted. RESULTS Fifty-four percent of the adolescents had a psychiatric history and 85% had psychiatric comorbidities. In adolescents undergoing surgery, excess weight loss was 46% after 1 year and 51% after 2years. For patients not receiving surgery, excess weight loss was 0.43% after 1 year (P=0.001). Compliance with medical treatment was the only significant element contributing to the decision to perform surgery. Results in terms of satisfaction and perception 1 and 2years after surgery were encouraging. CONCLUSION Bariatric surgery is feasible in young patients and produces good results in terms of excess weight loss. We argue that compliance with medical treatment is probably one of the most important elements for making the decision to perform bariatric surgery and in excess weight loss after surgery. We probably need to focus on the compliance of young patients and evaluate how this can be improved.
Collapse
Affiliation(s)
- E Riquin
- Pediatric Psychiatry Department, University Hospital of Angers, 4, rue Larrey, 49933 Angers cedex 9, France.
| | - F Schmitt
- Pediatric Surgery Department, University Hospital of Angers, 4, rue Larrey, 49933 Angers cedex 9, France
| | - N Bouhours-Nouet
- Pediatric Endocrinology Department, University Hospital of Angers, 4, rue Larrey, 49933 Angers cedex 9, France
| | - M Beaumesnil
- Centre de rééducation des Capucins, 28, rue des Capucins, B.P. 40329, 49103 Angers cedex 02, France
| | - M Dinomais
- Centre de rééducation des Capucins, 28, rue des Capucins, B.P. 40329, 49103 Angers cedex 02, France
| | - J Malka
- Pediatric Psychiatry Department, University Hospital of Angers, 4, rue Larrey, 49933 Angers cedex 9, France
| | - M Robin
- Pediatric Psychiatry Department, institut mutualiste Montsouris, 42, boulevard Jourdan, 75014 Paris, France
| | - R Coutant
- Pediatric Endocrinology Department, University Hospital of Angers, 4, rue Larrey, 49933 Angers cedex 9, France
| | - P Duverger
- Pediatric Psychiatry Department, University Hospital of Angers, 4, rue Larrey, 49933 Angers cedex 9, France
| |
Collapse
|
16
|
Schmitt F, Mariani A, Eyssartier E, Granry JC, Podevin G. Skills improvement after observation or direct practice of a simulated laparoscopic intervention. J Gynecol Obstet Hum Reprod 2018; 47:101-106. [DOI: 10.1016/j.jogoh.2017.12.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 12/11/2017] [Accepted: 12/27/2017] [Indexed: 01/22/2023]
|
17
|
Alix L, Decaux O, Moreau C, Viel J, Schmitt F, Seguret F, Jego P. Répartition et épidémiologie des gammapathies monoclonales en France : prévalence plus importante d’IgM et de maladie de Waldenström dans l’Ouest de la France. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Rossi ED, Bizzarro T, Martini M, Capodimonti S, Cenci T, Fadda G, Schmitt F, Larocca LM. Morphological features that can predict BRAF V600E -mutated carcinoma in paediatric thyroid cytology. Cytopathology 2016; 28:55-64. [PMID: 27256275 DOI: 10.1111/cyt.12350] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/04/2016] [Indexed: 12/22/2022]
Abstract
OBJECTIVE BRAFV600E represents the most common diagnostic marker in papillary thyroid carcinoma (PTC). A few papers have demonstrated the correlation between BRAFV600E and specific morphological findings on PTCs in the adult population. This is the first reported series investigating cytological morphological parameters in paediatric thyroid carcinoma. METHODS One hundred and nineteen paediatric samples (56 male and 63 female patients), diagnosed in the period between April 2013 and July 2015, were enrolled in the study. Fifteen patients with inadequate results were excluded. Cytological cases were processed with liquid-based cytology (LBC). BRAFV600E and immunocytochemistry for the VE1 antibody were performed on LBC. RESULTS The diagnostic series included 10 mutated and 94 wild-type (WT) cases. Twenty two percent surgical samples showed 96% cytohistological concordance. The morphological analysis revealed plump cells (abundant eosinophilic cytoplasm and PTC nuclei) in all 10 mutated cases with only four cases showing a focal (less than 20% of the cells) plump component. None of the WT showed plump cells. A sickle nuclear shape was seen only in the mutated cases. VE1 yielded 100% positivity on mutated cases with three cytohistological discrepancies. CONCLUSIONS The BRAFV600E mutation is also seen in paediatric cytology and the morphological features showed a high accuracy as both predictive mutational parameters and a helpful aid in management mainly of the aggressive BRAFV600E mutated carcinomas.
Collapse
Affiliation(s)
- E D Rossi
- Division of Anatomic Pathology and Histology, Università Cattolica del Sacro Cuore, "Agostino Gemelli" School of Medicine, Rome, Italy
| | - T Bizzarro
- Division of Anatomic Pathology and Histology, Università Cattolica del Sacro Cuore, "Agostino Gemelli" School of Medicine, Rome, Italy
| | - M Martini
- Division of Anatomic Pathology and Histology, Università Cattolica del Sacro Cuore, "Agostino Gemelli" School of Medicine, Rome, Italy
| | - S Capodimonti
- Division of Anatomic Pathology and Histology, Università Cattolica del Sacro Cuore, "Agostino Gemelli" School of Medicine, Rome, Italy
| | - T Cenci
- Division of Anatomic Pathology and Histology, Università Cattolica del Sacro Cuore, "Agostino Gemelli" School of Medicine, Rome, Italy
| | - G Fadda
- Division of Anatomic Pathology and Histology, Università Cattolica del Sacro Cuore, "Agostino Gemelli" School of Medicine, Rome, Italy
| | - F Schmitt
- Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Porto, Portugal.,Laboratorie National de Sante, Dudelange, Luxembourg
| | - L M Larocca
- Division of Anatomic Pathology and Histology, Università Cattolica del Sacro Cuore, "Agostino Gemelli" School of Medicine, Rome, Italy
| |
Collapse
|
19
|
Rettig L, Cortés R, Chu JH, Fisher IR, Schmitt F, Moore RG, Shen ZX, Kirchmann PS, Wolf M, Bovensiepen U. Persistent order due to transiently enhanced nesting in an electronically excited charge density wave. Nat Commun 2016; 7:10459. [PMID: 26804717 PMCID: PMC4737756 DOI: 10.1038/ncomms10459] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Accepted: 12/14/2015] [Indexed: 12/02/2022] Open
Abstract
Non-equilibrium conditions may lead to novel properties of materials with broken symmetry ground states not accessible in equilibrium as vividly demonstrated by non-linearly driven mid-infrared active phonon excitation. Potential energy surfaces of electronically excited states also allow to direct nuclear motion, but relaxation of the excess energy typically excites fluctuations leading to a reduced or even vanishing order parameter as characterized by an electronic energy gap. Here, using femtosecond time- and angle-resolved photoemission spectroscopy, we demonstrate a tendency towards transient stabilization of a charge density wave after near-infrared excitation, counteracting the suppression of order in the non-equilibrium state. Analysis of the dynamic electronic structure reveals a remaining energy gap in a highly excited transient state. Our observation can be explained by a competition between fluctuations in the electronically excited state, which tend to reduce order, and transiently enhanced Fermi surface nesting stabilizing the order. Whilst excited electronic states may exhibit unique non-equilibrium behavior, order is inhibited by fluctuations. Here, the authors use femtosecond photoemission spectroscopy to demonstrate transient stabilization of charge density wave order in rare earth tritellurides after near-infrared excitation.
Collapse
Affiliation(s)
- L Rettig
- Fakultät für Physik, Universität Duisburg-Essen, Lotharstr. 1, D-47057 Duisburg, Germany.,Fachbereich Physik, Freie Universität Berlin, Arnimallee 14, D-14195 Berlin, Germany
| | - R Cortés
- Fachbereich Physik, Freie Universität Berlin, Arnimallee 14, D-14195 Berlin, Germany.,Abteilung Physikalische Chemie, Fritz-Haber-Institut der MPG, Faradayweg 4-6, D-14195 Berlin, Germany
| | - J-H Chu
- Geballe Laboratory for Advanced Materials, Department of Applied Physics, Via Pueblo Mall, Stanford, California 94305, USA.,SLAC National Accelerator Laboratory, Stanford Institute for Material and Energy Sciences, Menlo Park, 94025 California, USA
| | - I R Fisher
- Geballe Laboratory for Advanced Materials, Department of Applied Physics, Via Pueblo Mall, Stanford, California 94305, USA.,SLAC National Accelerator Laboratory, Stanford Institute for Material and Energy Sciences, Menlo Park, 94025 California, USA
| | - F Schmitt
- Geballe Laboratory for Advanced Materials, Department of Applied Physics, Via Pueblo Mall, Stanford, California 94305, USA
| | - R G Moore
- SLAC National Accelerator Laboratory, Stanford Institute for Material and Energy Sciences, Menlo Park, 94025 California, USA
| | - Z-X Shen
- Geballe Laboratory for Advanced Materials, Department of Applied Physics, Via Pueblo Mall, Stanford, California 94305, USA.,SLAC National Accelerator Laboratory, Stanford Institute for Material and Energy Sciences, Menlo Park, 94025 California, USA
| | - P S Kirchmann
- SLAC National Accelerator Laboratory, Stanford Institute for Material and Energy Sciences, Menlo Park, 94025 California, USA
| | - M Wolf
- Fachbereich Physik, Freie Universität Berlin, Arnimallee 14, D-14195 Berlin, Germany.,Abteilung Physikalische Chemie, Fritz-Haber-Institut der MPG, Faradayweg 4-6, D-14195 Berlin, Germany
| | - U Bovensiepen
- Fakultät für Physik, Universität Duisburg-Essen, Lotharstr. 1, D-47057 Duisburg, Germany.,Fachbereich Physik, Freie Universität Berlin, Arnimallee 14, D-14195 Berlin, Germany
| |
Collapse
|
20
|
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol 2015; 26:2505-6. [PMID: 26467471 DOI: 10.1093/annonc/mdv478] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-879. [PMID: 25725046 DOI: 10.1093/annonc/mdv106] [Citation(s) in RCA: 116] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2014] [Accepted: 02/16/2015] [Indexed: 02/11/2024] Open
Abstract
BACKGROUND Using surrogate end points for overall survival, such as disease-free survival, is increasingly common in randomized controlled trials. However, the definitions of several of these time-to-event (TTE) end points are imprecisely which limits interpretation and cross-trial comparisons. The estimation of treatment effects may be directly affected by the definitions of end points. The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of TTE end points. We report guidelines for randomized cancer clinical trials (RCTs) in breast cancer. PATIENTS AND METHODS A literature review was carried out to identify TTE end points (primary or secondary) reported in publications of randomized trials or guidelines. An international multidisciplinary panel of experts proposed recommendations for the definitions of these end points based on a validated consensus method that formalize the degree of agreement among experts. RESULTS Recommended guidelines for the definitions of TTE end points commonly used in RCTs for breast cancer are provided for non-metastatic and metastatic settings. CONCLUSION The use of standardized definitions should facilitate comparisons of trial results and improve the quality of trial design and reporting. These guidelines could be of particular interest to those involved in the design, conducting, reporting, or assessment of RCT.
Collapse
Affiliation(s)
- S Gourgou-Bourgade
- Biostatistic Unit, Montpellier Cancer Institute, Montpellier; Data Center for Cancer Clinical Trials, CTD-INCa, Montpellier, France.
| | - D Cameron
- Edinburgh Cancer Research Centre, University of Edinburgh, Western General Hospital, Edinburgh, UK
| | - P Poortmans
- Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands
| | - B Asselain
- Department of Biostatistics, Institut Curie, Paris
| | - D Azria
- Department of Radiation Oncology, Montpellier Cancer Institute, Montpellier, France
| | - F Cardoso
- Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - R A'Hern
- Institute of Cancer Research, London, UK
| | - J Bliss
- Institute of Cancer Research, London, UK
| | - J Bogaerts
- EORTC Data Center (European Organization of Research and Treatment of Cancer - Statistics Department), Brussels, Belgium
| | - H Bonnefoi
- Institut Bergonié, Comprehensive Cancer Centre, Bordeaux
| | - E Brain
- Departments of Clinical Research and Medical Oncology, Institut Curie - Hôpital René Huguenin, Saint-Cloud
| | - M J Cardoso
- Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - B Chibaudel
- Department of Medical Oncology, Hôpital Saint-Antoine, Paris, France
| | - R Coleman
- FRCP, FRCPE YCR National Institute for Health Research Cancer Research Network (NCRN), Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield Cancer Research Centre, Sheffield, UK
| | - T Cufer
- University Clinic Golnik, Golnik, Slovenia
| | - L Dal Lago
- Institut Jules Bordet, University 'Libre' of Brussels, Brussels, Belgium
| | - F Dalenc
- Institut Claudius Régaud, Toulouse
| | - E De Azambuja
- Institut Jules Bordet, University 'Libre' of Brussels, Brussels, Belgium
| | - M Debled
- Institut Bergonié, Comprehensive Cancer Centre, Bordeaux
| | - S Delaloge
- Breast Cancer Group, Gustave Roussy Institute, Villejuif
| | | | - J Gligorov
- APHP Tenon - University Cancer Institute - Pierre & Marie Curie, Sorbonne University, Paris
| | | | - W Jacot
- Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France
| | - C Kirkove
- Université catholique Louvain, Louvain-la-Neuve, Belgium
| | - G MacGrogan
- Institut Bergonié, Comprehensive Cancer Centre, Bordeaux
| | - S Michiels
- Biostatistic and Epidemiology Unit, Gustave Roussy, Villejuif; University of Paris-Sud, Villejuif, France
| | - I Negreiros
- Breast Unit, Hospital CUF Descobertas, Lisbon, Portugal
| | - B V Offersen
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - F Penault Llorca
- Centre Jean Perrin, Clermont-Ferrand; ERTICA EA4677, UFR Medicine, University of Clermont-Ferrand 1, Clermont-Ferrand, France
| | - G Pruneri
- European Institute of Oncology, Milan; University of Milan, School of Medicine, Milan, Italy
| | - H Roche
- Institut Claudius Régaud, Toulouse
| | - N S Russell
- Department of Radiotherapy, The Netherlands Cancer Institute - Antoni van Leeuwnhoek Hospital, Amsterdam, The Netherlands
| | - F Schmitt
- IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto), Porto; Medical Faculty of Porto University, Porto, Portugal
| | - V Servent
- Oscar Lambret Comprehensive Cancer Center, Lille, France
| | - B Thürlimann
- Kantonsspital St Gallen, Breast Center, St Gallen, Switzerland
| | - M Untch
- Clinic for Gynecology, Gynecologic Oncology and Obstetrics-Interdisciplinary Breast Cancer Center, HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | - J A van der Hage
- Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam
| | - G van Tienhoven
- Academic Medical Center Amsterdam, Amsterdam, The Netherlands
| | - H Wildiers
- Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven; Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, Leuven, Belgium
| | - J Yarnold
- The Institute of Cancer Research, Royal Cancer Hospital, London, UK
| | - F Bonnetain
- Methodological and Quality of Life Unit in Oncology (EA3181), CHU Besançon, Besançon
| | - S Mathoulin-Pélissier
- Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux; Clinical Epidemiology Unit, INSERM CIC 14.01 (Clinical Epidemiology), Bordeaux
| | - C Bellera
- Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux; Clinical Epidemiology Unit, INSERM CIC 14.01 (Clinical Epidemiology), Bordeaux
| | - T S Dabakuyo-Yonli
- Biostatistics and Quality of Life Unit (EA4184), Centre Georges François Leclerc Comprehensive Cancer Centre, Dijon, France
| |
Collapse
|
22
|
Herbert A, Anic V, Cochand-Priollet B, Dina R, Ehya H, Eide ML, Fabre M, Field A, Kapila K, Kardum-Skelin I, Oliveira MH, Olszewski W, Önal B, Nasioutziki M, Nayar R, Nielsen K, Shabalova I, Schmitt F, Tötsch M, Wilson A, Vass L, Zeppa P. Training and practice of cytotechnologists: a discussion forum focused on Europe. Cytopathology 2014; 25:307-15. [DOI: 10.1111/cyt.12201] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/11/2014] [Indexed: 12/28/2022]
Affiliation(s)
- A. Herbert
- Cellular Pathology Department; St Thomas’ Hospital; Guy's and St Thomas’ NHS Foundation Trust; London UK
| | - V. Anic
- Department of Clinical Cytology and Cytogenetics; Merkur University Hospital; Zagreb Croatia
| | | | - R. Dina
- Histopathology Department; Imperial College NHS Trust; Hammersmith Hospital; London UK
| | - H. Ehya
- Department of Pathology; Fox Chase Cancer Center; Philadelphia PA USA
| | - M.-L. Eide
- Department of Pathology and Medical Genetics; Trondheim University Hospital; Trondheim Norway
| | - M. Fabre
- Department of Pathology; Gustave Roussy; Cancer Campus Grand Paris; Villejuif France
| | - A. Field
- Department of Anatomical Pathology; St Vincent's Hospital; Sydney NSW Australia
| | - K. Kapila
- Cytopathology Unit; Department of Pathology; Faculty of Medicine; Kuwait University; Kuwait Kuwait
| | - I. Kardum-Skelin
- Department of Clinical Cytology and Cytogenetics; Merkur University Hospital and School of Medicine; University of Zagreb; Zagreb Croatia
| | - M. H. Oliveira
- Laboratório de Anatomia Patológica; Hospital Beatriz Angelo; Loures Portugal
| | - W. Olszewski
- Department of Pathology; Institute of Oncology; Warsaw Poland
| | - B. Önal
- Department of Pathology and Cytology; Ankara Diskapi Teaching and Research Hospital; Ankara Turkey
| | - M. Nasioutziki
- Molecular Cytopathology Laboratory; Faculty of Medicine; AUTH; Hippokration Hospital; Thessaloniki Greece
| | - R. Nayar
- Cytopathology Laboratory; Northwestern Memorial Hospital; Chicago IL USA
| | - K. Nielsen
- Institute of Pathology; Aahus University Hospital; Aarhus Denmark
| | - I. Shabalova
- Russian Medical Academy of Postgraduate Education; Moscow Russia
| | - F. Schmitt
- Institute of Molecular Pathology and Immunology of the University of Porto; Porto Portugal
- Department of Laboratory Medicine and Pathobiology; Faculty of Medicine; University of Toronto; Toronto ON Canada
| | - M. Tötsch
- Institute of Cytology; University Hospital of Graz; Medical University of Graz; Graz Austria
| | - A. Wilson
- Department of Histopathology; Monklands Hospital; Airdrie UK
| | - L. Vass
- Department of Pathology/Cytology; University Hospital of Pest County; Kistarcsa Hungary
| | - P. Zeppa
- Anatomia Patologica; University of Salerno; Salerno Italy
| |
Collapse
|
23
|
Abstract
Despite significant advances in diagnosis, surgical techniques, general patient care, and local and systemic adjuvant therapies, metastatic disease remains the most critical condition limiting the survival of patients with breast cancer. Therefore, the development of effective treatment against late-arising metastasis has become the centre of clinical attention and is one of the current challenges in cancer research. A deeper understanding of the metastatic cascade is fundamental, and the need for repetitive tumour assessments for the evaluation of tumour evolution is a relatively new practice in routine medical care. As such, fine needle aspiration cytology (FNAC) is ideally placed to monitor biological changes in metastasis that may affect treatment and response. As FNAC is a minimally invasive method, it can be performed repeatedly with relatively little trauma, and selective ancillary tests can be applied to FNAC specimens, including for tumour whose primary nature is known. Herein, we review how the linear and parallel models explain metastatic dissemination, thus influencing therapeutic and clinical decisions, and how cytology, together with immunocytochemistry and molecular analysis, can be a tool for routine clinical practice and clinical trials aimed at metastatic disease with a special emphasis on breast cancer.
Collapse
Affiliation(s)
- D Martins
- IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
| | | | | |
Collapse
|
24
|
Schmitt F, Bouhours-Nouet N, Beaumesnil M, Dubois N, Coutant R, Topart P, Weil D, Podevin G. SFP PC-16 - Impact de l’anneau gastrique ajustable chez l’adolescent obèse. Arch Pediatr 2014. [DOI: 10.1016/s0929-693x(14)72166-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Geslin D, Schmitt F, Clermidi P, Fremond B, Gabielza M, Lardy H, Leboucher B, Marechaud M, Saliou A, Podevin G. SFCP CO-19 - Quels sont les facteurs échographiques anténataux prédictifs de laparoschisis compliqués ? Arch Pediatr 2014. [DOI: 10.1016/s0929-693x(14)71657-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
26
|
Theysohn J, Kraff O, Gerwig M, Timmann D, Schmitt F, Gizewski ER, Ladd ME, Ladd SC, Bitz AK. Vestibuläre Effekte einer 7 Tesla MRT-Kopfuntersuchung im Vergleich zu 1,5 und 0 Tesla. ROFO-FORTSCHR RONTG 2014. [DOI: 10.1055/s-0034-1372769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
27
|
Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J, Orsi F, Lotz G, Ferrucci P. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. ROFO-FORTSCHR RONTG 2014; 186:937-44. [PMID: 24729409 DOI: 10.1055/s-0034-1366081] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
PURPOSE Chemosaturation with percutaneous hepatic perfusion (PHP; Hepatic CHEMOSAT(®) Delivery System; Delcath Systems Inc, USA) is a minimally invasive, repeatable regional therapy for unresectable hepatic metastases. It uses a system of catheters and filters to isolate hepatic venous blood from the systemic circulation, allowing delivery of high-dose chemotherapy to the hepatic artery. Effluent hepatic venous blood is filtered before being returned to the systemic circulation, thereby reducing exposure to chemotherapy. We describe our experiences with chemosaturation-PHP at 2 European centers. MATERIALS AND METHODS 14 patients presented unresectable hepatic metastases from solid tumors; 13 received 1 - 3 sessions of chemosaturation-PHP. Melphalan 2.0 (n = 1) or 3.0 (n = 12) mg/kg was given as a 30-minute infusion into the hepatic artery. 12 patients were evaluable for tumor response. RESULTS One complete (cholangiocarcinoma, n = 1) and 6 partial responses (ocular, n = 3 or cutaneous melanoma, n = 3) were observed, 5 patients had stable disease (ocular melanoma, n = 3; breast cancer, n = 1; gastric cancer, n = 1). Mild to moderate filter-related toxicity (i. e. thrombocytopenia, anemia) was observed immediately post-procedure. Grade 3/4 melphalan-related pancytopenia developed after 1 - 2 weeks. All hematological events were managed effectively with transfusions and/or other supportive measures. The new high-efficiency filter showed milder toxicity and faster recovery. In one case, chemosaturation-PHP was abandoned prematurely due to heparin-induced vaginal bleeding, and one patient died due to retroperitoneal hemorrhage from heparin anti-coagulation. CONCLUSION Chemosaturation-PHP for non-resectable liver metastases is a feasible treatment option when performed by an experienced multi-disciplinary team. It may be a promising regional therapy for patients with no effective treatment options.
Collapse
Affiliation(s)
- T J Vogl
- Department of Diagnostic and Interventional Radiology, University Hospital of Frankfurt
| | - S Zangos
- Department of Diagnostic and Interventional Radiology, University Hospital of Frankfurt
| | - J E Scholtz
- Department of Diagnostic and Interventional Radiology, University Hospital of Frankfurt
| | - F Schmitt
- Department of Diagnostic and Interventional Radiology, University Hospital of Frankfurt
| | - S Paetzold
- Department of Dermatology, Venerology and Allergology, University Hospital of Frankfurt
| | - J Trojan
- Department of Medicine I, University Hospital of Frankfurt
| | - F Orsi
- Unit of Interventional Radiology, European Institute of Oncology, Milan
| | - G Lotz
- Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital of Frankfurt
| | - P Ferrucci
- Translational Research on Melanoma, European Institute of Oncology, Milan
| |
Collapse
|
28
|
Körtvelyessy P, Kluge C, Marquardt F, Knape S, Heinze HJ, Schmitt F. An adaptive strategy for detection of high-frequency oscillations in surface EEG/MEG recordings in an epilepsy patient. KLIN NEUROPHYSIOL 2014. [DOI: 10.1055/s-0034-1371249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Santos A, Pereira D, Paredes J, Schmitt F, Gama A. N-Cadherin Expression in Canine Malignant Mammary Tumours. J Comp Pathol 2014. [DOI: 10.1016/j.jcpa.2013.11.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
30
|
Smets Y, Stark CB, Lach S, Schmitt F, Wright CA, Wanke M, Ley L, Ziegler C, Pakes CI. Charge-induced distortion and stabilization of surface transfer doped porphyrin films. J Chem Phys 2013; 139:044703. [DOI: 10.1063/1.4815978] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Setsompop K, Kimmlingen R, Eberlein E, Witzel T, Cohen-Adad J, McNab JA, Keil B, Tisdall MD, Hoecht P, Dietz P, Cauley SF, Tountcheva V, Matschl V, Lenz VH, Heberlein K, Potthast A, Thein H, Van Horn J, Toga A, Schmitt F, Lehne D, Rosen BR, Wedeen V, Wald LL. Pushing the limits of in vivo diffusion MRI for the Human Connectome Project. Neuroimage 2013; 80:220-33. [PMID: 23707579 DOI: 10.1016/j.neuroimage.2013.05.078] [Citation(s) in RCA: 353] [Impact Index Per Article: 32.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2013] [Revised: 05/07/2013] [Accepted: 05/13/2013] [Indexed: 11/25/2022] Open
Abstract
Perhaps more than any other "-omics" endeavor, the accuracy and level of detail obtained from mapping the major connection pathways in the living human brain with diffusion MRI depend on the capabilities of the imaging technology used. The current tools are remarkable; allowing the formation of an "image" of the water diffusion probability distribution in regions of complex crossing fibers at each of half a million voxels in the brain. Nonetheless our ability to map the connection pathways is limited by the image sensitivity and resolution, and also the contrast and resolution in encoding of the diffusion probability distribution. The goal of our Human Connectome Project (HCP) is to address these limiting factors by re-engineering the scanner from the ground up to optimize the high b-value, high angular resolution diffusion imaging needed for sensitive and accurate mapping of the brain's structural connections. Our efforts were directed based on the relative contributions of each scanner component. The gradient subsection was a major focus since gradient amplitude is central to determining the diffusion contrast, the amount of T2 signal loss, and the blurring of the water PDF over the course of the diffusion time. By implementing a novel 4-port drive geometry and optimizing size and linearity for the brain, we demonstrate a whole-body sized scanner with G(max) = 300 mT/m on each axis capable of the sustained duty cycle needed for diffusion imaging. The system is capable of slewing the gradient at a rate of 200 T/m/s as needed for the EPI image encoding. In order to enhance the efficiency of the diffusion sequence we implemented a FOV shifting approach to Simultaneous MultiSlice (SMS) EPI capable of unaliasing 3 slices excited simultaneously with a modest g-factor penalty allowing us to diffusion encode whole brain volumes with low TR and TE. Finally we combine the multi-slice approach with a compressive sampling reconstruction to sufficiently undersample q-space to achieve a DSI scan in less than 5 min. To augment this accelerated imaging approach we developed a 64-channel, tight-fitting brain array coil and show its performance benefit compared to a commercial 32-channel coil at all locations in the brain for these accelerated acquisitions. The technical challenges of developing the over-all system are discussed as well as results from SNR comparisons, ODF metrics and fiber tracking comparisons. The ultra-high gradients yielded substantial and immediate gains in the sensitivity through reduction of TE and improved signal detection and increased efficiency of the DSI or HARDI acquisition, accuracy and resolution of diffusion tractography, as defined by identification of known structure and fiber crossing.
Collapse
Affiliation(s)
- K Setsompop
- AA Martinos Center for Biomedical Imaging, Dept. of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Schmitt F, Caldari D, Corradini N, Gicquel P, Leclair MD, Podevin G. Tolérance et efficacité de la gastrostomie d’alimentation. Arch Pediatr 2013. [DOI: 10.1016/j.arcped.2013.02.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
33
|
Robichon C, Annereau JP, Gomes B, Pillon A, de Vries L, Cussac D, Meyer N, Lamant L, Kruczynski A, Guilbaud N, Kluza J, Jendoubi M, Corazao-Rozas P, Andre F, Jonneaux A, Guerreschi P, Formstecher P, Mortier L, Marchetti PHI, Bozkurt E, Atmaca H, Uzunoglu S, Uslu R, Karaca B, Erenpreisa J, Jackson TR, Huna A, Salmina K, Innashkina I, Jankevics E, Townsend PA, Cragg MS, Atmaca H, Bozkurt E, Uzunoglu S, Uslu R, Karaca B, Ramos SP, Bin M, Neto MDS, Curvello R, de Souza ACS, Nunes M, Weiswald LB, Vrignaud P, Vacher S, Turlotte E, Richon S, Roman-Roman S, Bieche I, Dangles-Marie V, Morais-Santos F, Pinheiro C, Vieira A, Schmitt F, Paredes J, Baltazar F, Zhang T, Lee YW, Rui YF, Cheng TY, Li G, Sreelatha KH, Reshma RS, Veena S, Rakesh SN, Thara S, Jem P, Priya S, Veena S, Sreelatha KH, Reshma RS, Rakesh SN, Priya S. Poster session 5. Translational research. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Morais-Santos F, Pinheiro C, Vieira A, Schmitt F, Paredes J, Baltazar F. Contribution of Monocarboxylate Transporters to the Aggressive Phenotype of Breast Cancer. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt047.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Rettig L, Cortés R, Chu JH, Fisher I, Schmitt F, Kirchmann P, Moore R, Shen ZX, Wolf M, Bovensiepen U. Time-resolved Fermi surface mapping of the charge density wave material DyTe 3. EPJ Web of Conferences 2013. [DOI: 10.1051/epjconf/20134103025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Pereira D, Vieira A, Schmitt F, Paredes J, Gama A. Targeting Cancer Stem Cells in Canine Mammary Cancer. J Comp Pathol 2013. [DOI: 10.1016/j.jcpa.2012.11.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
37
|
Pereira D, Alves A A, Paredes J, Schmitt F, Gama A. Altered p120 ctn Expression in Canine Mammary Carcinomas is Associated with Poor Survival. J Comp Pathol 2013. [DOI: 10.1016/j.jcpa.2012.11.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Marinšek ZP, Nolde N, Kardum-Skelin I, Nizzoli R, Onal B, Rezanko T, Tani E, Ostović KT, Vielh P, Schmitt F, Kocjan G. Multinational study of oestrogen and progesterone receptor immunocytochemistry on breast carcinoma fine needle aspirates. Cytopathology 2012; 24:7-20. [PMID: 23082931 DOI: 10.1111/cyt.12024] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To collect data on the variability of immunocytochemical (ICC) procedures used to detect oestrogen/progesterone receptors (ER/PR) on cytological material; to test the reproducibility of results; and to identify the crucial points in the ICC procedures that affect the result. METHODS Ten laboratories from eight countries participated in a two-part study. In the first part, one of the participants (the coordinator) prepared and distributed cytospins from a fine needle aspirate of a primary breast carcinoma. Laboratories performed ICC staining for ER/PR according to their own methods on the test slides and in-house positive controls. Slides were returned to the coordinator together with information on the preparation of positive control slides and the ICC methodology used. In the second part, obligatory methods of fixation and antigen retrieval were specified. Evaluation of results included grading the number of positive cells, staining intensity, background staining, cytoplasmic staining, sample condition and cellularity. Participants evaluated their own results, which were subsequently evaluated by the coordinator. RESULTS There was great variability in the preparation of slides for in-house controls and ICC methodology. The outcome of ICC staining of in-house control slides was excellent in two laboratories, adequate in three, sub-optimal in four and inadequate in one. Only six obtained a positive reaction on the test slides and not all were of a high quality. Results of the second run were greatly improved in terms of cellularity of in-house positive control slides, and scores for the percentage of stained cells and staining intensity of control and test slides. Cytospins and monolayer (ThinPrep(®)) preparations were superior to direct smears; methods of fixation and antigen retrieval were the key points in the staining process. CONCLUSIONS Our experience points to the need for guidelines for hormonal receptor determination and external quality control on cytological material, in order for cytological methods to be used in routine clinical practice with a suitable degree of confidence.
Collapse
Affiliation(s)
- Z P Marinšek
- Department of Cytopathology, Institute of Oncology, Ljubljana, Slovenia.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Schmitt F, Vielh P, Zeppa P. Cytology for pathologists: two sides of the same coin or different views of the same side? Cytopathology 2012; 23:345-6. [DOI: 10.1111/cyt.12018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Catherwood MA, Schmitt F, Salto-Tellez M. Molecular diagnostics and the training of future tissue- and cell-based pathologists. Cytopathology 2012; 23:283-5. [DOI: 10.1111/cyt.12015] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
41
|
Martins D, Sousa B, Paredes J, Schmitt F. mTOR Expression in Basal-Like Breast Cancer and the Ability of Everolimus to Inhibit the Invasion Cancer Cell Capacity. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32914-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
42
|
Albergaría A, Nobre A, Vieira A, Ricardo S, Sousa B, Seruca R, Paredes J, Schmitt F. 488 TAp63 Counteracts Invasive and Stem Cell Properties Mediated by P-cadherin in Breast Cancer Cells. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71159-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
43
|
Santos F, Pinheiro C, Miranda-Goncalves V, Vieira A, Paredes J, Schmitt F, Baltazar F. 453 Regulation of the Metabolic Profile of Breast Cancer Cells by Hypoxia. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71126-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Ricardo S, Gerhard R, Schmitt F, Paredes J. 53P Claudins Expression in Breast Cancer: High or Low, What to Expect? Ann Oncol 2012. [DOI: 10.1016/s0923-7534(19)65698-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
45
|
Singhal D, Hack N, Abner E, Schmitt F, Nelson P, Jicha G. Examining Instability and Reversion in the Diagnosis of Mild Cognitive Impairment (P04.207). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p04.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
46
|
Singhal D, Abner E, Schmitt F, Nelson P, Jicha G. Antipsychotic Use Is Not Associated with an Increased Burden of Cerebrovascular Pathology at Autopsy (S04.004). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.s04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
47
|
Metcalf A, Abner E, Schmitt F, Kryscio R, Stiles N, Jicha G. Frontal Release Signs Predict Decline in Subjects with Intact Cognition and Mild Cognitive Impairment (P01.082). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p01.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
48
|
Johnston S, Vishik IM, Lee WS, Schmitt F, Uchida S, Fujita K, Ishida S, Nagaosa N, Shen ZX, Devereaux TP. Evidence for the importance of extended Coulomb interactions and forward scattering in cuprate superconductors. Phys Rev Lett 2012; 108:166404. [PMID: 22680740 DOI: 10.1103/physrevlett.108.166404] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/06/2011] [Revised: 12/13/2011] [Indexed: 06/01/2023]
Abstract
The prevalent view of the high-temperature superconducting cuprates is that their essential low-energy physics is captured by local Coulomb interactions. However, this view been challenged recently by studies indicating the importance of longer-range components. Motivated by this, we demonstrate the importance of these components by examining the electron-phonon (e-ph) interaction with acoustic phonons in connection with the recently discovered renormalization in the near-nodal low-energy (~8-15 meV) dispersion of Bi(2)Sr(2)CaCu(2)O(8+δ). By studying its nontrivial momentum and doping dependence we conclude a predominance of forward scattering arising from the direct interplay between the e-ph and extended Coulomb interactions. Our results thus demonstrate how the low-energy renormalization can provide a pathway to new insights into how these interactions interplay with one another and influence pairing and dynamics in the cuprates.
Collapse
Affiliation(s)
- S Johnston
- Stanford Institute for Materials and Energy Sciences, SLAC National Accelerator Laboratory and Stanford University, Menlo Park, California 94305, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
AIMS To assess perceptions of child behaviour and parenting stress among the parents of young children with hypoplastic left heart syndrome (HLHS) and other forms of functionally univentricular heart defects (UVH). METHODS As part of our prospective nation-wide neurodevelopmental follow-up study, the parents of 23 patients with HLHS, 14 with UVH and 46 healthy controls at the mean age of 18 months received the questionnaires Child Behavior Checklist and Parenting Stress Index. RESULTS The reported level of total parenting stress was significantly higher among the mothers (mean score 241 vs 205, p < 0.001) and fathers (235 vs 202, p = 0.003) of patients with HLHS compared with those of controls. The parents of patients with HLHS reported significantly more total (mean T score 52 vs 45, p = 0.005) and internalizing (51 vs 41, p < 0.001) behaviour problems than the controls, but among the syndrome scales, a significant difference was only found in somatic complaints. The parents of patients with UVH did not report more parenting stress or emotional problems than the controls. CONCLUSION Hypoplastic left heart syndrome, a severe congenital heart defect, increases parenting stress. The reported emotional maladjustment in affected children might in part be owing to somatic complaints.
Collapse
Affiliation(s)
- A Sarajuuri
- Children's Hospital, University of Helsinki, Finland.
| | | | | | | | | |
Collapse
|
50
|
Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, Schmitt F, Baltazar F. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011; 26:1279-86. [PMID: 21870331 DOI: 10.14670/hh-26.1279] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The goal of the present work was to evaluate the correlation of glucose transporter 1 (GLUT1) and carbonic anhydrase IX (CAIX) with the monocarboxylate transporters 1 (MCT1) and 4 (MCT4) and their chaperone, CD147, in breast cancer. The clinico-pathological value of GLUT1 and CAIX was also evaluated. For that, we analysed the immunohistochemical expression of GLUT1 and CAIX, in a large series of invasive breast carcinoma samples (n=124), previously characterized for MCT1, MCT4 and CD147 expression. GLUT1 expression was found in 46% of the cases (57/124), while CAIX was found in 18% of the cases (22/122). Importantly, both MCT1 and CD147, but not MCT4, were associated with GLUT1 and CAIX expression. Also, GLUT1 and CAIX correlated with each other. Concerning the clinico-pathological values, GLUT1 was associated with high grade tumours, basal-like subtype, absence of progesterone receptor, presence of vimentin and high proliferative index as measured by Ki-67. Additionally, CAIX was associated with large tumour size, high histological grade, basal-like subtype, absence of estrogen and progesterone receptors and presence of basal cytokeratins and vimentin expression. Finally, patients with CAIX positive tumours had a significantly shorter disease-free survival. The association between MCT1 and both GLUT1 and CAIX may result from hypoxia-mediated metabolic adaptations, which confer a glycolytic, acid-resistant and more aggressive phenotype to cancer cells.
Collapse
Affiliation(s)
- C Pinheiro
- Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Braga, Portugal
| | | | | | | | | | | | | | | |
Collapse
|